These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22431958)

  • 1. Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2.
    da Silva Voorham JM; Rodenhuis-Zybert IA; Ayala Nuñez NV; Colpitts TM; van der Ende-Metselaar H; Fikrig E; Diamond MS; Wilschut J; Smit JM
    PLoS One; 2012; 7(3):e29957. PubMed ID: 22431958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A fusion-loop antibody enhances the infectious properties of immature flavivirus particles.
    Rodenhuis-Zybert IA; Moesker B; da Silva Voorham JM; van der Ende-Metselaar H; Diamond MS; Wilschut J; Smit JM
    J Virol; 2011 Nov; 85(22):11800-8. PubMed ID: 21880758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.
    Tsai WY; Chen HL; Tsai JJ; Dejnirattisai W; Jumnainsong A; Mongkolsapaya J; Screaton G; Crowe JE; Wang WK
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30185598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Idiotypic Antibodies Specific to prM Monoantibody Prevent Antibody Dependent Enhancement of Dengue Virus Infection.
    Wang M; Yang F; Huang D; Huang Y; Zhang X; Wang C; Zhang S; Zhang R
    Front Cell Infect Microbiol; 2017; 7():157. PubMed ID: 28536674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. prM-reactive antibodies reveal a role for partially mature virions in dengue virus pathogenesis.
    Dowd KA; Sirohi D; Speer SD; VanBlargan LA; Chen RE; Mukherjee S; Whitener BM; Govero J; Aleshnick M; Larman B; Sukupolvi-Petty S; Sevvana M; Miller AS; Klose T; Zheng A; Koenig S; Kielian M; Kuhn RJ; Diamond MS; Pierson TC
    Proc Natl Acad Sci U S A; 2023 Jan; 120(3):e2218899120. PubMed ID: 36638211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Anti-Premembrane Antibody as a Serocomplex-Specific Marker To Discriminate Zika, Dengue, and West Nile Virus Infections.
    Hsieh SC; Tsai WY; Tsai JJ; Stone M; Simmons G; Busch MP; Lanteri M; Stramer SL; Balmaseda A; Harris E; Wang WK
    J Virol; 2021 Sep; 95(19):e0061921. PubMed ID: 34232731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies against immature virions are not a discriminating factor for dengue disease severity.
    Rodenhuis-Zybert IA; da Silva Voorham JM; Torres S; van de Pol D; Smit JM
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003564. PubMed ID: 25760350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substitution of the precursor peptide prevents anti-prM antibody-mediated antibody-dependent enhancement of dengue virus infection.
    Wang Y; Si LL; Guo XL; Cui GH; Fang DY; Zhou JM; Yan HJ; Jiang LF
    Virus Res; 2017 Feb; 229():57-64. PubMed ID: 27939945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. prM-antibody renders immature West Nile virus infectious in vivo.
    Colpitts TM; Rodenhuis-Zybert I; Moesker B; Wang P; Fikrig E; Smit JM
    J Gen Virol; 2011 Oct; 92(Pt 10):2281-2285. PubMed ID: 21697345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.
    Beltramello M; Williams KL; Simmons CP; Macagno A; Simonelli L; Quyen NT; Sukupolvi-Petty S; Navarro-Sanchez E; Young PR; de Silva AM; Rey FA; Varani L; Whitehead SS; Diamond MS; Harris E; Lanzavecchia A; Sallusto F
    Cell Host Microbe; 2010 Sep; 8(3):271-83. PubMed ID: 20833378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immature dengue virus: a veiled pathogen?
    Rodenhuis-Zybert IA; van der Schaar HM; da Silva Voorham JM; van der Ende-Metselaar H; Lei HY; Wilschut J; Smit JM
    PLoS Pathog; 2010 Jan; 6(1):e1000718. PubMed ID: 20062797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera.
    de Alwis R; Williams KL; Schmid MA; Lai CY; Patel B; Smith SA; Crowe JE; Wang WK; Harris E; de Silva AM
    PLoS Pathog; 2014 Oct; 10(10):e1004386. PubMed ID: 25275316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional importance of dengue virus maturation: infectious properties of immature virions.
    Zybert IA; van der Ende-Metselaar H; Wilschut J; Smit JM
    J Gen Virol; 2008 Dec; 89(Pt 12):3047-3051. PubMed ID: 19008392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
    BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization.
    Nelson S; Jost CA; Xu Q; Ess J; Martin JE; Oliphant T; Whitehead SS; Durbin AP; Graham BS; Diamond MS; Pierson TC
    PLoS Pathog; 2008 May; 4(5):e1000060. PubMed ID: 18464894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody.
    Luo YY; Feng JJ; Zhou JM; Yu ZZ; Fang DY; Yan HJ; Zeng GC; Jiang LF
    BMC Microbiol; 2013 Aug; 13():194. PubMed ID: 23987307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection.
    Slon Campos JL; Poggianella M; Marchese S; Mossenta M; Rana J; Arnoldi F; Bestagno M; Burrone OR
    PLoS One; 2017; 12(7):e0181734. PubMed ID: 28742857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states.
    Lee PD; Mukherjee S; Edeling MA; Dowd KA; Austin SK; Manhart CJ; Diamond MS; Fremont DH; Pierson TC
    J Virol; 2013 Dec; 87(24):13729-40. PubMed ID: 24109224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.
    Smith SA; Nivarthi UK; de Alwis R; Kose N; Sapparapu G; Bombardi R; Kahle KM; Pfaff JM; Lieberman S; Doranz BJ; de Silva AM; Crowe JE
    J Virol; 2016 Jan; 90(2):780-9. PubMed ID: 26512092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.